New complement regulator exposed.

@article{Lesher2009NewCR,
  title={New complement regulator exposed.},
  author={Allison M. Lesher and Wen-chao Song},
  journal={Blood},
  year={2009},
  volume={114 12},
  pages={
          2363-4
        }
}
Abstract 2363 Poster Board II-340 Background: Clinical trials report that FR as initial therapy in symptomatic CLL produces an overall response rate of 90% and significantly improves progression-free survival (PFS) and overall survival (OS) compared retrospectively to F alone [Byrd Blood 2003, 2005] and that FCR (F, cyclophosphamide and R) improves response rates and PFS compared to FC alone [Hallek ASH 2008]. FR has been the standard initial therapy for CLL/SLL in British Columbia (BC… CONTINUE READING

Citations

Publications citing this paper.

In vitro and in vivo models of renal ischemia reperfusion injury

VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED